Search Results
Jan 21, 2026, 07:04 ET Thesis Gold Intersects 38.00 Metres of 3.62 g/t Au at Steve Zone, Ranch Project
to potentially host high-grade gold (Au) mineralization that was not included in the current Mineral Resource Estimate or the Pre-feasibility Study (PFS) economic model. Previous drilling in 2022 and 2023 (9 holes total) intersected broad zones of lower-grade gold mineralization; however, geological interpretation
More news about: Thesis Gold Inc.
Jan 21, 2026, 07:00 ET Defense Metals Appoints Robin Jones as Vice President, Projects
as detailed in the Company's 2025 Pre Feasibility Study ("PFS") |(refer Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI43-101") . The PFS, showed the economic potential of the deposit, supporting
More news about: Defense Metals Corp.
Jan 20, 2026, 07:00 ET Rapid Growth of High Grade Core Continues at La Verde
financial metrics of Hot Chili's March 2025 Pre-feasibility Study (PFS).Costa Fuego is significantly leveraged to both copper and gold price, both of which are materially higher than assumptions used in the Company's PFS. Long-term consensus prices for both commodities sit at US$4.51/lb
More news about: Hot Chili Limited
Jan 20, 2026, 06:00 ET West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack
industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system.
More news about: West Pharmaceutical Services, Inc.
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), duration of response (DoR), and time to next treatment
More news about: AbbVie
Jan 16, 2026, 08:00 ET American Lithium Minerals, Inc Announces Strategic Acquisition of 19% Interest in Cunningham Mining Ltd
undeveloped gold deposits globally, measured by gold reserves, and is in close proximity to the Placer claim. An updated Preliminary Feasibility Study (PFS) estimates proven and probable reserves totaling 38.8 million ounces of gold and 10.2 billion pounds of copper. The gold recovered was fine-grained flakes
More news about: American Lithium Minerals, Inc
Jan 16, 2026, 05:05 ET Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs
functional reliability of large volume injection systems and promote greater comfort and safety for the patients," said Paolo Ferrigno, Product Manager, PFS & Cartridges, Datwyler.Overcoming the Challenges of On-body Delivery for Large-Volume TherapiesTransitioning from hospital-based
More news about: Datwyler
Jan 16, 2026, 03:05 ET transcosmos releases health promotion support services for local governments
an example of health promotion for local governments, Kunitachi City, Tokyo, launched Kunitachi City Health Promotion Plan using the Pay For Success (PFS) model in October 2024. transcosmos participates in this project as a BPO service provider. The project incorporates various health point systems to
More news about: transcosmos inc.
Jan 15, 2026, 20:38 ET Mayfair Gold Files Technical Report for Fenn-Gib Gold Project
Forward-looking information in this news release includes, but is not limited to, statements regarding the design, development and execution of the Project, the PFS demonstrating the strong economics and free cash flow potential associated with developing the Project as a targeted, high-grade operation that can be
More news about: Mayfair Gold Corp.
Jan 14, 2026, 21:24 ET Thesis Gold Files Pre-Feasibility Technical Report for the Lawyers-Ranch Gold-Silver Project
SEDAR+ of the Pre-feasibility Study (the "2025 PFS") for the wholly owned Lawyers-Ranch gold-silver Project (the "Project", or "Lawyers-Ranch"), located in the Toodoggone District, in Northern British Columbia. Results from the 2025 PFS were announced by the Company on December 1, 2025.
More news about: Thesis Gold Inc.
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS) with TECVAYLI® compared to standard of care as early as second line.1
More news about: Johnson & Johnson
Jan 13, 2026, 22:54 ET Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
compared to the PD-1 monoclonal antibody regimen, significantly prolonged patients' overall survival (OS) and progression-free survival (PFS). Both OS (HR=0.49, P=0.025) and PFS (HR=0.43, P=0.006) demonstrated statistically significant improvements. The full study has been accepted for publication in the Journal
More news about: Akeso, Inc.
Jan 13, 2026, 03:26 ET Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
antitumor activity following IMC002 treatment in a heavily pretreated setting.Further analyses indicated that IMC002 provided clinically meaningful PFS benefits in third-line and later-line GC/GEJ patients, comparing favorably with historical outcomes reported for this population. Together with its well-tolerated
More news about: Immunofoco Biotechnology
Jan 12, 2026, 22:07 ET WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
to provide GMP-compliant manufacturing on a global scale.DP5, WuXi Biologics' first commercial pre-filled syringe (PFS) manufacturing facility, delivers industry-leading PFS solutions to clients with production lines covering both clinical and commercial manufacturing. DPPC provides clients with
More news about: WuXi Biologics
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
follows positive final results from the Company's VERSATILE-002 trial, which showed promising median overall survival and durable PFS, with the proposed amendment changing the PFS endpoint to a primary endpoint that can be evaluated earlier with significant statistical power.The amendment retains median
More news about: USA News Group
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
free survival (PFS) data, from ongoing registrational Phase 2/3 OptimUM-02 trial of the darovasertib and crizotinib combination in first line (1L) patients with HLA*A2-negative metastatic UM (mUM) are expected in Q1 '26Randomized PFS analysis is based on the first 130 PFS events from
More news about: IDEAYA Biosciences, Inc.
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
with disease progression, second-line options remain limited, with historical response rates of 32 to 36 percent and median progression-free survival (PFS) of 5.4 to 6.4 months using EGFR inhibitors and chemotherapy.5,6,7,8,9,10 Research has shown that MET alterations are a frequent cause
More news about: Johnson & Johnson
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
partial response, with 1 patient pending confirmation).The median progression-free survival (mPFS) was 7.3 months with a 6-month PFS rate of 59%. The median overall survival (mOS) was 13.2 months and still maturing while 6-month OS rate was 93%. Responses were
More news about: Phanes Therapeutics, Inc.
Jan 08, 2026, 17:18 ET ARIS MINING EXPANDS HIGH-GRADE SEGOVIA RESERVE AND RESOURCE ESTIMATES
gold project, where a new Preliminary Economic Assessment has been completed and a Prefeasibility Study is in progress. Following completion of the PFS, Toroparu will be positioned to advance toward construction.Aris Mining also owns the Soto Norte gold project, where a Prefeasibility Study has
More news about: Aris Mining Corporation
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
trial of ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL once the pre-specified number of approximately 262 progression-free survival (PFS) events is reached and data are available. Publication of the full results is anticipated by the end of 2026. Assuming positive results, a supplemental
More news about: ADC Therapeutics SA
Jan 08, 2026, 10:30 ET VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
CLDN18.2-positive advanced gastric or GEJ cancer. In combination with chemotherapy, zolbetuximab demonstrated statistically significant improvements in PFS and OS compared with placebo plus chemotherapy in the SPOTLIGHT and GLOW Phase 3 clinical trials.2,3 In SPOTLIGHT and GLOW, the incidence
More news about: Astellas Pharma Inc.
Jan 08, 2026, 07:15 ET ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
runway into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Jan 08, 2026, 07:00 ET Mayfair Delivers Robust Pre-Feasibility Study for the Fenn-Gib Gold Project
Pre-Feasibility Study ("PFS") for the Fenn-Gib gold project in the Timmins Gold District of Ontario, Canada. The study has been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"). The NI 43-101 Technical Report for the PFS will be
More news about: Mayfair Gold Corp.
Jan 08, 2026, 06:15 ET Energy Fuels Announces Updated Feasibility Study for Toliara Rare Earth and HMS Project in Madagascar Confirming World-Class Scale and Economics, Including $1.8 Billion NPV and Ramping Up to Over $500 Million of Expected Annual EBITDA
and NI 43-101 (Canada), which consolidates and supersedes the 2021 definitive feasibility study (DFS) and 2024 monazite-focused prefeasibility study (PFS) prepared in compliance with JORC (Australia)."The FS confirms what we've known since we acquired the project in 2024. Vara Mada is
More news about: Energy Fuels Inc.
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
HR+/HER2- disease (3.7 months) and HER2-Low disease (3.9 months), with patients exhibiting a favorable Neutrophil-to-Lymphocyte Ratio achieving median PFS of 4.4 months versus 2.6 months in those with unfavorable NLR. "We are very excited to see the robust and positive biomarker data, which may enable
More news about: USA News Group